nihao guest [ sign in / register ]
2024-6-19 6:48:30

Furey C, Scher G, Ye N, Kercher L, DeBeauchamp J,. Development of a nucleoside-modified mRNA vaccine against clade H5 highly pathogenic avian influenza virus. Nat Commun. 2024 May 23;15(1):4350
submited by kickingbird at May, 24, 2024 19:55 PM from Nat Commun. 2024 May 23;15(1):4350

mRNA lipid nanoparticle (LNP) vaccines would be useful during an influenza virus pandemic since they can be produced rapidly and do not require the generation of egg-adapted vaccine seed stocks. Highly pathogenic avian influenza viruses from H5 clade are circulating at unprecedently high levels in wild and domestic birds and have the potential to adapt to humans. Here, we generate an mRNA lipid nanoparticle (LNP) vaccine encoding the hemagglutinin (HA) glycoprotein from a clade H5 isolate. The H5 mRNA-LNP vaccine elicits strong T cell and antibody responses in female mice, including neutralizing antibodies and broadly-reactive anti-HA stalk antibodies. The H5 mRNA-LNP vaccine elicits antibodies at similar levels compared to whole inactivated vaccines in female mice with and without prior H1N1 exposures. Finally, we find that the H5 mRNA-LNP vaccine is immunogenic in male ferrets and prevents morbidity and mortality of animals following H5N1 challenge. Together, our data demonstrate that a monovalent mRNA-LNP vaccine expressing H5 is immunogenic and protective in pre-clinical animal models.

See Also:

Latest articles in those days:

[Go Top]    [Close Window]

Related Pages:
Learn about the flu news, articles, events and more
Subscribe to the weekly F.I.C newsletter!


Site map  |   Contact us  |  Term of use  |  FAQs |  粤ICP备10094839号-1
Copyright ©www.flu.org.cn. 2004-2024. All Rights Reserved. Powered by FIC 4.0.1